Mehmet Ağar
Research Subjects
Mehmet Ağar has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Asena Ayar Madenli
Liv Vadistanbul Hospital, Gynecology and obstetrics, Istanbul, Turkey; Istinye University Faculty of Medicine, Department of Gynecology of Obstetrics, Istanbul, Turkey
1 shared publication - Halime Çalı Öztürk
Department of Obstetrics and Gynecology, Bezmialem University,Istanbul,Turkey
1 shared publication - Murat Önal
Gynolife IVF Clinic, Lefkosa, Cyprus
1 shared publication - Nur Dokuzeylül Güngör
Department of Obstetrics and Gynecology, Reproductive Endocrinology and IVF Unit, School of Medicine, Bahcesehir University, Istanbul, Turkey
1 shared publication Şebnem Alanya Tosun
Department of Obstetrics and Gynecology Giresun University Faculty of Medicine , Giresun Turkey
1 shared publication
Latest Publications
- Open Access
- 28 June 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (3) , 183-188
Evaluation of the relationship between insulin resistance and different phenotypes of polycystic ovary syndrome
Aims: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women. Hyperinsulinemia and insulin resistance (IR) are the most important metabolic abnormalities that affect these patients. This study aimed to investigate the variables related to IR in patients with different PCOS phenotypes. Methods: This retrospective study included 389 women diagnosed with PCOS in Bezmialem Hospital between november 2020 and september 2022. Information about patients was collected through their electronic records. PCOS was diagnosed based on the Rotterdam criteria, and four phenotypes of A (oligoovulation+ hyperandrogenism+PCO), B (oligoovulation+hyperandrogenism), C (hyperandrogenism +PCO), and D (oligoovulation+absent PCO) were considered for PCOS. The homeostatic model assessment for ınsulin resistance (HOMA-IR) was used to evaluate IR. The Mann-Whitney U test was performed to study the difference between the groups. Results: The highest value of HOMA-IR was for the phenotype B group, and the lowest value was for the phenotype C group. However, the difference between the groups was not significant (p=0.221). Estradiol and free T4 were significantly higher in the phenotype A group (p≤0.001). Thyroid-stimulating hormone (TSH), prolactin, anti-mullerian hormone (AMH), fasting insulin, total testosterone, and red blood cell distribution width (RDW) were significantly higher in the phenotype B group (p≤0.001). Total cholesterol, high density lipoprotein (HDL), leukocyte, basophil, and monocyte were significantly higher in the phenotype C group (p≤0.001). Also, MPV values were significantly higher in the phenotype D group (p≤0.001). Conclusion: The results showed that the variables related to IR in phenotypes A and B of PCOS are higher than in other phenotypes.
- 28 June 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (3) , 183-188
Open AccessEvaluation of the relationship between insulin resistance and different phenotypes of polycystic ovary syndrome
Aims: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women. Hyperinsulinemia and insulin resistance (IR) are the most important metabolic abnormalities that affect these patients. This study aimed to investigate the variables related to IR in patients with different PCOS phenotypes. Methods: This retrospective study included 389 women diagnosed with PCOS in Bezmialem Hospital between november 2020 and september 2022. Information about patients was collected through their electronic records. PCOS was diagnosed based on the Rotterdam criteria, and four phenotypes of A (oligoovulation+ hyperandrogenism+PCO), B (oligoovulation+hyperandrogenism), C (hyperandrogenism +PCO), and D (oligoovulation+absent PCO) were considered for PCOS. The homeostatic model assessment for ınsulin resistance (HOMA-IR) was used to evaluate IR. The Mann-Whitney U test was performed to study the difference between the groups. Results: The highest value of HOMA-IR was for the phenotype B group, and the lowest value was for the phenotype C group. However, the difference between the groups was not significant (p=0.221). Estradiol and free T4 were significantly higher in the phenotype A group (p≤0.001). Thyroid-stimulating hormone (TSH), prolactin, anti-mullerian hormone (AMH), fasting insulin, total testosterone, and red blood cell distribution width (RDW) were significantly higher in the phenotype B group (p≤0.001). Total cholesterol, high density lipoprotein (HDL), leukocyte, basophil, and monocyte were significantly higher in the phenotype C group (p≤0.001). Also, MPV values were significantly higher in the phenotype D group (p≤0.001). Conclusion: The results showed that the variables related to IR in phenotypes A and B of PCOS are higher than in other phenotypes.
- Open Access
- 27 March 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (2) , 89-93
The pregnancy results were not affected from the administration day of Depot GnRH agonists in artificial cycle frozen-thawed embryo transfers
Aim: In frozen-thawed embryo transfers (FET), Gonadotropin-Releasing Hormone (GnRH) agonists have recently been used to improve implantation results. It is preferred to administer it in the luteal phase of the previous cycle. The objective was to compare the effects of different administration days of depot GnRH agonists on implantation and pregnancy rates in the artificial cycle of FET. Material and Method: A retrospective case-control study was conducted in an in vitro fertilization (IVF) center in a university hospital, including all women starting an artificial cycle of FET. One thousand two hundred and twenty-seven (n:1227) FET cycles were scanned from the files from October 2014 to December 2021. Depot agonists (Lucrin depot 3.75 mg sc Abbott USA.-leuprolide acetate) were used in 219 patients with endometriosis. In 58 patients, it was administered on day 21 of the previous cycle (Group 1), and in 161 patients, it was administered on day 2 of the same cycle (Group 2). Results: This study showed no statistically significant difference between the two groups in laboratory parameters and endometrial thickness (p>0.05). There was no statistically significant association between the abort rate and transfer day (p>0.05). There was no statistically significant association between the pregnancy results and transfer day (p>0.05). The ongoing pregnancy rate (OPR) rate was relatively high in the second group compared to the twenty-first day of the previous cycle (87/161(54%) vs. 30/58 (51.7%)). The biochemical pregnancy was relatively high in the second-day group compared to the twenty-first day of the previous cycle (62/161(38.5%) vs. 21/58 (36.2%)). The abort rate was relatively high in the twenty-first-day group compared to the second day of the cycle (25/87(28.75%) vs. 9/30(30%)). Conclusion: In conclusion, the impacts of various administration days of depot Gonadotropin-releasing hormone (GnRH) agonists on implantation and pregnancy rates were not statistically significant.
- 27 March 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (2) , 89-93
Open AccessThe pregnancy results were not affected from the administration day of Depot GnRH agonists in artificial cycle frozen-thawed embryo transfers
Aim: In frozen-thawed embryo transfers (FET), Gonadotropin-Releasing Hormone (GnRH) agonists have recently been used to improve implantation results. It is preferred to administer it in the luteal phase of the previous cycle. The objective was to compare the effects of different administration days of depot GnRH agonists on implantation and pregnancy rates in the artificial cycle of FET. Material and Method: A retrospective case-control study was conducted in an in vitro fertilization (IVF) center in a university hospital, including all women starting an artificial cycle of FET. One thousand two hundred and twenty-seven (n:1227) FET cycles were scanned from the files from October 2014 to December 2021. Depot agonists (Lucrin depot 3.75 mg sc Abbott USA.-leuprolide acetate) were used in 219 patients with endometriosis. In 58 patients, it was administered on day 21 of the previous cycle (Group 1), and in 161 patients, it was administered on day 2 of the same cycle (Group 2). Results: This study showed no statistically significant difference between the two groups in laboratory parameters and endometrial thickness (p>0.05). There was no statistically significant association between the abort rate and transfer day (p>0.05). There was no statistically significant association between the pregnancy results and transfer day (p>0.05). The ongoing pregnancy rate (OPR) rate was relatively high in the second group compared to the twenty-first day of the previous cycle (87/161(54%) vs. 30/58 (51.7%)). The biochemical pregnancy was relatively high in the second-day group compared to the twenty-first day of the previous cycle (62/161(38.5%) vs. 21/58 (36.2%)). The abort rate was relatively high in the twenty-first-day group compared to the second day of the cycle (25/87(28.75%) vs. 9/30(30%)). Conclusion: In conclusion, the impacts of various administration days of depot Gonadotropin-releasing hormone (GnRH) agonists on implantation and pregnancy rates were not statistically significant.